A study supported the ellipsoid zone loss as a meaningful biomarker that can be used to guide clinical trial design in ...

Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to ...

Memory loss is the tell-tale sign that you or a loved one could be developing dementia. However, science shows your eyes ...

Aldeyra ’s Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

Have you heard about the Whoodle? Admittedly, it's not a common word you'll hear in everyday conversation, but canine lovers ...

Faster thinning of cpRNFL and mGCIPL is associated with visual field progression in glaucoma, with rates of –1.02 and –1.04 ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Luke Littler is on course to defend his World Darts Championship title after storming into the quarter-finals. The ...